KLF5, a new player and new target in the permanently changing set of pancreatic cancer molecular drivers
- Authors: Zinovyeva M.V.1, Kostina M.B.1, Chernov I.P.1, Kondratyeva L.G.1, Sverdlov E.D.1
-
Affiliations:
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
- Issue: Vol 42, No 6 (2016)
- Pages: 606-611
- Section: Minireview
- URL: https://journals.rcsi.science/1068-1620/article/view/228180
- DOI: https://doi.org/10.1134/S1068162016060157
- ID: 228180
Cite item
Abstract
Pancreatic cancer is one of the most aggressive tumor types characterized by chemotherapy resistance and high metastatic activity. Recent studies revealed new genes, which are likely to be actively involved in the regulation of the processes occurring in the pancreas, as well as in the development of cancer in this organ. This review is devoted to the description of one of the recently revealed genes, KLF5, which seems to be a promising target for therapeutic intervention in the most widespread type of pancreatic cancer, ductal adenocarcinoma.
About the authors
M. V. Zinovyeva
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Author for correspondence.
Email: mzinov@mail.ru
Russian Federation, Moscow, 117997
M. B. Kostina
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: mzinov@mail.ru
Russian Federation, Moscow, 117997
I. P. Chernov
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: mzinov@mail.ru
Russian Federation, Moscow, 117997
L. G. Kondratyeva
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: mzinov@mail.ru
Russian Federation, Moscow, 117997
E. D. Sverdlov
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: mzinov@mail.ru
Russian Federation, Moscow, 117997